

2024

Laffont CM, Lapeyra O, Mangal D, Dobbins R. A single-dose study to evaluate the relative bioavailability, safety, and tolerability of monthly extended-release buprenorphine at alternative injection locations in adult participants with opioid use disorder. *Clin Drug Investig.* 2024 Dec;44(12):939-949. doi: 10.1007/s40261-024-01406-7. Epub 2024 Nov 14.

Rockhill KM, Bau GE, DeVeaugh-Geiss A, Chilcoat H, Dart R, Iwanicki J, Black JC. Buprenorphine, oxycodone, hydrocodone, and methadone mortality in the United States (2010–2017). *J Am Coll Emerg Physicians Open.* 2024 Oct 23;5(5):e13338. doi: 10.1002/emp2.13338.

Byard SJ, Carey JS. The identification of naloxone-related drug product degradants. *Organic Proc Res Dev.* 2024 Aug 29;28(9):3645-60.

Skolnick P, Paavola J, Heidbreder C. Synthetic opioids have disrupted conventional wisdom for treating opioid overdose. *Drug Alcohol Depend Rep.* 2024 Aug 13;12:100268. doi: 10.1016/j.dadr.2024.100268.

Heidbreder C, Greenwald MK, Le Foll B, Skolnick P. Editorial: Discovery, development and implementation of improved options for treating opioid overdose in the synthetic opioid era. *Front Psychiatry.* 2024 Jul 11;15:1443304. doi: 10.3389/fpsyt.2024.1443304.

Ellison M, Hutton E, Webster L, Skolnick P. Reversal of opioid-induced respiratory depression in healthy volunteers: comparison of intranasal nalmefene and intranasal naloxone. *J Clin Pharmacol.* 2024 Jul;64(7):828-839. doi: 10.1002/jcph.2421.

Laffont CM, Purohit P, Delcamp N, Gonzalez-Garcia I, Skolnick P. Comparison of intranasal naloxone and intranasal nalmefene in a translational model assessing the impact of synthetic opioid overdose on respiratory depression and cardiac arrest. *Front Psychiatry.* 2024 Jun 17;15:1399803. doi: 10.3389/fpsyt.2024.1399803.

Rademeyer K, Thompson ML, Mullen W. Examining current policies and barriers regarding medications for opioid use disorder within the criminal justice system. *Corrections Today.* Summer 2024;(86:2):24-32.

Abdel-Sattar M, Cook S, Wheeler A, Mullen W, Maiese BA, Heidbreder C, Santoro W. Provider and payer perspectives on the impact of the COVID-19 pandemic on patients with opioid use disorder in the United States: Multi-stakeholder in-depth interviews. *Am Health Drug Benefits*. 2024 May;Web Exclusives, Original Research, Clinical.

Murray CM, Fox JC, Heidbreder C, Young M. A novel, non-opioid, selective orexin-1 receptor antagonist for the treatment of substance use disorders. *Neuroscience Applied*. 2024;3:104053. doi: 10.1016/j.nsa.2024.104053.

Walling DP, Shinde SN, Pogoda JM, Kharidia J, Laffont CM. An open-label study to assess monthly risperidone injections (180 mg) following switch from daily oral risperidone (6 mg) in stable schizophrenic patients. *Clin Drug Investig*. 2024 Apr;44(4):251-260. doi: 10.1007/s40261-024-01347-1.

Skolnick P. Comment on: Can intranasal nalmefene reduce the number of opioid overdose deaths? *Clin Pharmacol Drug Dev*. 2024 Mar;13(3):317-318. doi: 10.1002/cpdd.1382.

Carvalho AT, Dourado DF, Spratt J, Caswell JM, Skvortsov T, Quinn DJ, Carey JS, Moody TS. Enzyme screening and engineering for N-and O-Demethylation: Key steps in the synthesis of buprenorphine. *Org Process Res Dev*. 2024 Feb 16;28(3):729-37.

Miller EA, DeVeau-Geiss AM, Chilcoat HD. Opioid use disorder (OUD) and treatment for opioid problems among OUD symptom subtypes in individuals misusing opioids. *Drug Alcohol Depend Rep*. 2024 Feb 14;10:100220. doi: 10.1016/j.dadr.2024.100220.

Mariani JJ, Dobbins RL, Heath A, Gray F, Hassman H. Open-label investigation of rapid initiation of extended-release buprenorphine in patients using fentanyl and fentanyl analogs. *Am J Addict*. 2024 Jan;33(1):8-14. doi: 10.1111/ajad.13484.

Crystal R, Ellison M, Purdon C, Skolnick P. Pharmacokinetic properties of an FDA-approved intranasal nalmefene formulation for the treatment of opioid overdose. *Clin Pharmacol Drug Dev*. 2024 Jan;13(1):58-69. doi: 10.1002/cpdd.1312.